Articles tagged with Parkinsons Disease
Researchers at the University of Luxembourg have successfully grown brain-like cultures from human stem cells, mirroring the structure and function of the midbrain. This breakthrough allows for the study of Parkinson's disease mechanisms and potential treatments, as well as reducing animal testing in brain research.
Researchers found UM-Palmitoylethanolamide to slow down Parkinson's disease progression and disability, improving non-motor and motor aspects of daily living. The study used ultra-micronized palmitoylethanolamide as an add-on therapy in advanced PD patients, with significant reductions in symptoms.
Researchers have developed a way to deliver drugs to specific types of neurons in the brain, allowing for more precise study and treatment of neurological diseases. The new method, DART, reveals how movement difficulties in Parkinson's Disease are controlled by the AMPA receptor, offering a new approach to treating the disease.
A research team from the University of Freiburg has developed a new method to create microprobes that can grow into neural tissue without causing inflammation. These probes can deliver strong signals even after twelve weeks, opening up new possibilities for diagnoses and treatments for conditions like Parkinson's.
A recent study published in Neurology found that people with hepatitis B are 76% more likely to develop Parkinson's disease than those without the virus. Those with hepatitis C have a 51% increased risk. The research linked both viruses to an increased risk of Parkinson's disease, contradicting previous findings on hepatitis B.
A team of chemists from Konstanz University has made a significant discovery about the effects of selective mutations on the alpha-synuclein protein. By applying magnetic probes to the protein, they found that these changes disturb the binding of alpha-synuclein to membranes.
Researchers propose a new approach to treating Parkinson's disease by identifying specific symptoms and molecular features of individual patients. By developing biomarkers and tailoring therapies to distinct patient subtypes, scientists aim to improve treatment outcomes and potentially slow or cure the disease.
A University of Leicester study found that folinic acid can protect neurons in fruit flies with Parkinson's disease, offering potential hope for people with early-onset forms of the condition. The researchers believe that supplementing folinic acid could be a faster and more effective treatment option than developing new drugs.
Researchers at Salk Institute find that changing dopamine levels can alter upcoming choices, suggesting new avenues for treating Parkinson's and OCD. The study uses advanced techniques to measure dopamine concentration in mice brains, revealing a tight association between brain chemistry and decision-making.
Researchers discovered a connection between the SV2C protein and dopamine release in the brain, suggesting that drug therapies targeting SV2C may be beneficial for PD patients. The study found altered SV2C levels only in PD brains among patients with various neurodegenerative diseases.
Research finds a strong association between Parkinson's disease and stroke, with a higher incidence of ischemic stroke among those with Parkinson's. This link is similar to that between stroke and Alzheimer's disease.
Researchers at the University of Leicester have discovered a genetic 'switch' called ATF4 that plays a key role in Parkinson's disease. By targeting this gene, they hope to develop tailored interventions that can prevent or delay neuronal loss.
Researchers are exploring a new infusion therapy that could help smooth out movement for patients with Parkinson's by providing constant levodopa levels and stimulating dopamine receptors. The therapy aims to reduce off-time and increase on-time movement, improving overall quality of life.
Researchers identified cardiolipin, a mitochondrial lipid, as a potential target for reducing Parkinson's symptoms. Blocking the FASN protein increased cardiolipin levels and improved mitochondrial function, providing new insights into the disease.
A Yale University review of animal studies found that therapies successful in animals fail in humans due to early intervention timing and narrow study designs. The researchers highlight the need for more accurate translation from animal models to human trials.
A new study suggests a simple blood test can differentiate between Parkinson's disease and atypical parkinsonism disorders as accurately as a spinal fluid test. Researchers found that concentrations of neurofilament light chain protein in the blood can discriminate between these diseases.
Researchers discovered two distinct neural networks controlling the balance between speed and accuracy when making decisions. The subthalamic nucleus region plays a key role in this process, with one network requiring more information for accurate decisions and another lowering the threshold for quick choices.
A recent study published in Archives of Physical Medicine and Rehabilitation found that hand-grip strength is a reliable indicator of physical function decline in Parkinson's patients. The researchers used a portable monitoring device to measure muscle activity, showing that the test was conclusive and easy to administer.
A study found that two problem proteins known to cause Parkinson's disease are chemically linked, suggesting a common target for a single drug. Reducing one protein leads to an increase in the other, which can be mitigated by a treatment targeting the link.
Research at Lund University found that both neural pathways in the striatum, called direct and indirect pathway, work together to control movements, not independently. This discovery may lead to new treatments for movement disorders like Parkinson's disease by targeting both pathways.
Researchers have shed light on the relationship between misfolded alpha-synuclein protein and Parkinson's disease, identifying key genes and cellular processes involved. The study provides new insights into the underlying mechanisms of synucleinopathies, paving the way for developing patient-specific treatments.
A Norwegian study from the University of Bergen has identified key mechanisms behind Parkinson's disease, which may lead to future treatments. The research suggests that mitochondrial DNA damage is a primary cause of the disease, and that healthy brain cells can compensate for this damage by producing more DNA.
A synthesized steroid called squalamine has been shown to prevent the buildup of a lethal protein implicated in neurodegenerative diseases like Parkinson's. In an animal model, squalamine reduced the toxicity of alpha-synuclein clumps and protected healthy human neuronal cells from damage.
Researchers found that squalamine inhibits the early formation of toxic alpha-synuclein aggregates and suppresses their toxicity. The compound was tested in cell cultures, animal models, and human neuronal cells, showing promising results.
Researchers found that increasing niacin levels boosts NAD compound for energy generation and DNA repair, potentially protecting against Parkinson's. The study suggests repurposing cancer drugs to protect faulty mitochondria in Parkinson's disease.
Researchers found that chemicals extracted from prickly pear and brown seaweed improve cellular and animal models of neurodegenerative proteinopathies. The study suggests these substances may target pathways affected by multiple neurodegenerative conditions.
A laboratory study found that alpha-synuclein, a protein involved in Parkinson's disease, can travel from the brain to the stomach via specific nerve pathways. The protein was detected in gastric nerve terminals six months after its initial midbrain expression.
Duke University researchers have developed a new approach to deep brain stimulation that reduces energy consumption by up to 75% without compromising treatment efficacy. The algorithm uses computational evolution to design tailored patterns for individual patients, leading to improved symptoms and reduced battery replacement procedures.
A study of over 6.5 million Ontario residents found that those living within 50 meters of high-traffic roads had a seven percent higher likelihood of developing dementia compared to those further away. The risk increased with proximity, but not for Parkinson's disease or multiple sclerosis.
Richard Myers is investigating the Cyclin G-associated kinase (GAK) gene and its role in Parkinson's disease. His research aims to understand how increasing GAK levels may prevent cell death in PD.
Welders exposed to low levels of manganese exhibit neurological symptoms similar to Parkinson's disease, including slow movement and difficulty speaking. Current OSHA safety standards may not protect workers from the dangers of welding fumes.
A study published in Neurology found that welders who work with manganese fumes are more likely to develop Parkinson's-like symptoms. The researchers analyzed data from 886 workers and found that cumulative exposure to manganese was associated with a yearly increase in movement problems.
Researchers have found that activating the protein Nrf2 can restore normal levels of disease-causing proteins in cells, preventing cell death. In models of Parkinson's and Huntington's diseases, Nrf2 was shown to protect cells against the disease better than any other treatment.
A new study reveals that brain stimulation can improve timing abilities in mice lacking dopamine, a key player in Parkinson's disease. The breakthrough finding suggests that targeted brain stimulation could be used to treat cognitive problems caused by PD and possibly other conditions.
Researchers at the University of Helsinki have successfully corrected Parkinson's disease motor symptoms in mice using a PREP blocker treatment. The treatment, which blocks the formation of alpha-synuclein aggregates, restored motor skills and cleared brain accumulations within two weeks.
Researchers have developed a diabetes drug that slows experimental Parkinson's disease progression by regulating mitochondrial function and reducing inflammation. Human trials are set to begin next year, offering hope for the first treatment to target the underlying disease.
Researchers found significant alterations in brain networks of PD patients with mild cognitive impairment, indicating complex structural brain network disruption rather than individual white matter degeneration. The study suggests using MRI to monitor the disease and predict cognitive complications.
Researchers detect misfolded alpha-synuclein aggregates in cerebrospinal fluid to diagnose Parkinson's disease. The Protein Misfolding Cyclic Amplification technology detects small amounts of the protein, correlating with disease severity.
A study found that gut microbes exacerbate motor symptoms in a mouse model of Parkinson's disease, but antibiotic treatment and germ-free environments reduced motor deficits. The research could lead to new treatments for the neurodegenerative disease.
Researchers at Caltech discovered a novel link between the gut microbiome and Parkinson's disease, finding that gut bacteria promote hallmark pathology, neuroinflammation, and motor dysfunction. The study suggests targeting the gut microbiome may provide a new approach for diagnosing and treating PD.
Researchers at Caltech discovered a functional link between bacteria in the intestines and Parkinson's disease, showing that changes in gut bacterial populations contribute to motor skill deterioration. The study found that an imbalance in short-chain fatty acids regulates brain inflammation and symptoms of PD.
Researchers have made a breakthrough discovery on the formation and dissociation of pathogenic α-synuclein fibrils in Parkinson's disease, providing new insights into its progression. The study shows how high hydrostatic pressure breaks apart these toxic fibrils, shedding light on potential strategies for treating PD.
Patients with Parkinson's disease exhibit significant cognitive deficits when experiencing a drop in blood pressure upon standing up, known as orthostatic hypotension. These deficits reverse when they lie down and their blood pressure returns to normal.
A new study finds that GBA gene mutations are associated with increased cognitive decline in Parkinson's patients, who carry one defective copy of the gene. Patients with a more severe mutation showed a 217% increased risk of cognitive impairment within ten years of diagnosis.
Researchers at Iowa State University found a gene mutation linked to an accelerated onset of Parkinson's disease in Caucasians, with those under 50 experiencing symptoms 5 years earlier and a 45% increased risk. The study also highlights the importance of blood cholesterol levels, which are directly related to dopamine production.
Researchers used whole-brain MRI mapping to reveal pathological alterations in brain iron distribution. They found excess iron in areas like the substantia nigra and decreased iron content in previously overlooked regions, such as the dentate nucleus.
Researchers developed a new imaging technique that allows studying protein misfolding and toxicity in neurodegenerative diseases. The technique enables visualizing changes in protein molecules' surfaces, shedding light on the mechanisms behind these devastating diseases.
Researchers explore therapeutic interventions like light, sound, and electrical energy to resynchronize damaged neurons in the brain. Neuroplasticity can be harnessed to treat a range of conditions, from bad habits to chronic pain syndromes.
A collaboration of 32 researchers found a genetic mutation in the PINK1 gene that confers a risk for developing Parkinson's disease earlier than expected. The study showed that a specific mutation impairs the PINK1-PARKIN pathway, leading to damaged mitochondria accumulation and neurodegeneration.
Researchers found that combining virtual reality with treadmill training reduced fall frequency and risk for at least six months after training. The intervention improved both physical mobility and cognitive aspects of safe walking.
Researchers have adapted a facial analysis software to quantify how often patients' eyes closed when instructed to keep them open, finding a correlation with clinician ratings. The new program has the potential to help study facial tics and twitches in other contexts, including Tourette Syndrome, schizophrenia, and Parkinson's disease.
Researchers discover a cellular mechanism by which brain deactivates and then gradually reactivates neurons in the temporal association cortex. This discovery challenges the idea that all neurons are present and fully active from birth.
A recent study suggests that an enzyme deficiency in Krabbe's disease could contribute to mechanisms underlying Parkinson's disease and other neurodegenerative disorders. The protective myelin coating around nerve cells is compromised due to galactosylceramidase deficiency, a condition with currently no cure.
Researchers at the University of Copenhagen have found that adding the substance NAD+ to mice and roundworms can extend life and delay aging processes. The study suggests that NAD+ plays a key role in maintaining cellular health and repairing genes, with potential benefits for patients with Alzheimer's and Parkinson's disease.
A team of scientists identified how amyloid beta, associated with Alzheimer's, can induce cellular changes leading to Parkinson's. This discovery may provide an explanation for the co-occurrence of these neurodegenerative conditions and help researchers find ways to prevent such cases.
CVT-301, an inhaled form of levodopa, is being studied for its potential to restore motor function in people with Parkinson's disease experiencing OFF periods. The Phase 3 clinical program aims to confirm the efficacy and safety profile of CVT-301.
Researchers at Johns Hopkins Medicine identified a protein that enables toxic alpha-synuclein aggregates to spread in the brain. A treatment strategy blocking this protein's action may slow Parkinson's disease progression, as antibodies already in clinical trials for cancer therapy show protective effects.
Researchers found that exposure to bacterial proteins can cause brain proteins to misfold and lead to inflammation in the brain. The study suggests that gut bacteria may play a role in initiating these diseases, potentially leading to new treatments.
Researchers discovered that intestinal cells' immune response acts like detectives to identify damaged machinery within neurons and discard defective parts, protecting vital neurons. This innate mechanism, originating in the intestine, may hold the key to preventing Parkinson's disease.
A massive MRI study identified seven genetic hotspots regulating brain growth, memory, and reasoning, as well as predicting the onset of Parkinson's disease. The research supports the notion that brain size can be used to measure 'brain reserve' and promote resilience to age-related brain diseases.